195070-89-4

Basic information

• Product Name: methyl 2-(4-isopropylphenyl)-2-oxoacetate
• Synonyms: methyl 2-(4-isopropylphenyl)-2-oxoacetate
• CAS NO: 195070-89-4
• Molecular Weight: 206.241
• Mol File: 195070-89-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-isopropylphenyl)-2-oxoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-isopropylphenyl)-2-oxoacetate(195070-89-4)
• EPA Substance Registry System: methyl 2-(4-isopropylphenyl)-2-oxoacetate(195070-89-4)

Safety Data

• Hazardous Substances Data: 195070-89-4(Hazardous Substances Data)

Upstream product

• 5781-53-3 monomethyl oxalyl chloride 
• 98-82-8 Isopropylbenzene 
• 67-56-1 methanol 
• 645-13-6 4-isopropylacetophenone 
• 16216-94-7 methyl 2-(4-isopropylphenyl)acetate 

Downstream Products

• 195070-90-7 Methyl 2-hydroxyimino-2-(4isopropylphenyl)acetate 

Relevant articles and documents

Stoichiometric Photochemical Carbene Transfer by Bamford–Stevens Reaction

The photolysis of diazoalkanes is a timely strategy to conduct carbene-transfer reactions under mild and metal-free reaction conditions, and has developed as an important alternative to conventional metal-catalyzed carbene-transfer reactions. One of the major limitations lies within the rapidly occurring side reaction of the carbene intermediate with remaining diazoalkane molecules that result in the use of an excess of the reaction partner and thus impacts on the reaction efficiency. Herein, we describe a protocol that takes advantage of the in situ generation of donor–acceptor diazoalkanes by Bamford–Stevens reaction. Following this strategy, the concentration of the diazoalkane reaction partner can be minimized to reduce unwanted side reactions and to now conduct photochemical carbene transfer reactions under stoichiometric reaction conditions. We have explored this approach in the C?H and N?H functionalization and cyclopropanation reaction of N-heterocycles and could demonstrate the applicability of this method in 51 examples.

beta -thiopropionyl-aminoacid derivatives and their use as beta -lactamase inhibitors

PCT No. PCT/EP97/00516 Sec. 371 Date Jan. 13, 1999 Sec. 102(e) Date Jan. 13, 1999 PCT Filed Feb. 3, 1997 PCT Pub. No. WO97/30027 PCT Pub. Date Aug. 21, 1997A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a beta -lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R1 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C1-6)alkylcarbonyloxy, (C1-6)alkoxycarbonyl, formyl or (C1-6)alkylcarbonyl group, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl(C1-6)alkyl, heterocyclyl or heterocyclyl(C1-6)alkyl; R2 is hydrogen, (C1-6)alkyl or aryl(C1-6)alkyl; R3 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms, (C3-7)cycloalkyl, fused aryl(C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl-(CHR10)m-X-(CHR11)n, heterocyclyl or heterocyclyl-(CHR10)m-X-(CHR11)n, where m is 0 to 3, n is 1 to 3, each R10 and R11 is independently hydrogen or (C1-4)alkyl and X is O, S(O)x where x is 0-2, or a bond; R4 is hydrogen, or an in vivo hydrolysable acyl group; and R5 and R6 are independently hydrogen and (C1-6)alkyl or together represent (CH2)p where p is 2 to 5. Some compounds are claimed per se.